Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)‘s stock had its “overweight” rating reissued by research analysts at Piper Jaffray Companies in a research report issued to clients and investors on Wednesday. They presently have a $30.00 price objective on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target would suggest a potential upside of 40.38% from the company’s previous close.

Several other analysts also recently issued reports on ADMS. Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Adamas Pharmaceuticals in a report on Sunday, September 17th. BidaskClub downgraded Adamas Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 17th. Mizuho restated a “buy” rating and set a $48.00 price objective (up previously from $26.00) on shares of Adamas Pharmaceuticals in a report on Tuesday. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Noble Financial restated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $36.67.

Shares of Adamas Pharmaceuticals (NASDAQ ADMS) opened at 21.32 on Wednesday. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $23.84. The stock’s 50 day moving average is $18.21 and its 200-day moving average is $17.22. The stock’s market capitalization is $480.00 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. Adamas Pharmaceuticals’s quarterly revenue was down 90.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.78) EPS. On average, equities research analysts expect that Adamas Pharmaceuticals will post ($3.77) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Rating Reiterated by Piper Jaffray Companies” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/adamas-pharmaceuticals-inc-adms-rating-reiterated-by-piper-jaffray-companies/1579778.html.

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Adamas Pharmaceuticals by 10.3% in the 1st quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock valued at $12,537,000 after purchasing an additional 66,825 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Adamas Pharmaceuticals by 212.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after purchasing an additional 41,436 shares during the period. Emerald Advisers Inc. PA increased its holdings in shares of Adamas Pharmaceuticals by 2.7% in the 2nd quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock valued at $9,317,000 after purchasing an additional 14,042 shares during the period. Geode Capital Management LLC increased its holdings in shares of Adamas Pharmaceuticals by 4.9% in the 1st quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock valued at $2,201,000 after purchasing an additional 5,920 shares during the period. Finally, Parametric Portfolio Associates LLC increased its holdings in shares of Adamas Pharmaceuticals by 153.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock valued at $1,956,000 after purchasing an additional 67,654 shares during the period. Institutional investors own 69.24% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.